Related Experiment Video
Updated: Jun 15, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice
Gijs W Landman1, Kornelis J J van Hateren, Nanne Kleefstra
1Internal Medicine and Diabetes Centre, Isala clinics, Zwolle, the Netherlands. g.w.d.landman@isala.nl
Background:
The relationship between the degree of glycaemic control and mortality remains an important topic of discussion.
Aim:
This study aimed to investigate this relationship.
Design Of Study:
Prospective cohort study.
Setting:
Primary care.
Method:
A total of 1145 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) in 1998. Their survival status was recorded in September 2004. Mortality ratios were calculated using standardised mortality ratios (SMRs). Associations between haemoglobin A(1c) (HbA(1c)) levels and mortality were studied with a Cox proportional hazard model. HbA(1c) levels were studied as continuous and as categorical variables.
Results:
A total of 335 patients died after a median follow-up period of 5.8 years. The SMR (95% confidence interval [CI]) for total mortality was 1.86 (95% CI = 1.66 to 2.06) and 2.24 (95% CI = 1.91 to 2.61) for cardiovascular mortality. For each 1% increase in HbA(1c) there was a 21% increase in the hazard ratio for total mortality. When compared with the target HbA(1c) group (HbA(1c) 6.5-7%), the group with very poor glycaemic control (HbA1c >9%) had a hazard ratio of 2.21 (95% CI = 1.42 to 3.42) for total mortality. The group with normal glycaemic control (HbA(1c) <6.5%) had a hazard ratio of 1.00 (95% CI = 0.46 to 2.19) for total mortality.
Conclusion:
HbA(1c) level was associated with mortality and this effect seemed largely attributable to patients who were in really poor glycaemic control. The absence of differences in mortality in the groups with lower HbA(1c) levels supports the position that there is no basis for continually decreasing the therapeutic target HbA(1c) level in patients with type 2 diabetes mellitus.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes: Symptoms, Diagnosis, and Complications
Type II Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
